Late bleeding events in TAVI patients receiving vitamin K antagonists or direct oral anticoagulants
Revista Española de Cardiología (English Edition) · 2024
DOI: 10.1016/j.rec.2024.03.013 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Revista Española de Cardiología (English Edition), 2024. Verfasst von Alberto Alperi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Área del Corazón, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain; Instituto de Investigación Sanitaria del Principado de Asturia…. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Vitamin K, Atrial Fibrillation, Aortic Valve Stenosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION AND OBJECTIVES: The optimal chronic antithrombotic regimen for patients with atrial fibrillation undergoing transcatheter aortic valve implantation (TAVI) remains uncertain. Our aim was to compare the incidence of late bleeding events between patients on direct oral anticoagulants (DOACs) and those on vitamin-K antagonists (VKA). METHODS: This single-center observational study included TAVI patients requiring oral anticoagulation at discharge between 2015 and 2021. The primary endpoint was any clinically significant bleeding event. Secondary endpoints were stroke, heart failure, and all-cause mortality. RESULTS: A total of 702 TAVI procedures were performed, with 297 patients requiring oral anticoagulation at discharge. Among them, 206 (69.4%) received VKA and 91 (30.6%) received DOAC. Baseline clinical, procedural and in-hospital characteristics did not significantly differ between groups, except for better renal function among DOAC patients. The median length of follow-up was 2.8 years. The risk of bleeding events was higher in patients receiving DOACs than in those receiving VKA (HR, 2.27; 95%CI, 1.21-4.26; incidence of 9.7 and 4.2 events per 100 patient-years of follow-up for DOAC and VKA patients, respectively). There were no statistically significant differences in the rates of stroke (HR, 1.28; 95%CI, 0.4-4.3), heart failure hospitalization (HR, 0.92; 95%CI, 0.46-1.86), or all-cause mortality (HR, 1.02; 95%CI, 0.68-1.55). CONCLUSIONS: In older patients undergoing TAVI and receiving anticoagulant therapy for atrial fibrillation, the use of DOAC was associated with a higher risk of late bleeding events than VKA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Área del Corazón, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain; Instituto de Investigación Sanitaria del Principado de Asturias, ISPA, Asturias, Spain.
- Área del Corazón, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain.
- Área del Corazón, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain; Instituto de Investigación Sanitaria del Principado de Asturias, ISPA, Asturias, Spain; Universidad de Oviedo, Oviedo, Asturias, Spa…
Zitieren
APA
Alperi, A., Ptaszynski, R., Pascual, I., Del Valle, R., Hernández-Vaquero, D., Almendárez, M., Antuna, P., Ludeña, R., Morís, C., & Avanzas, P. (2024). Late bleeding events in TAVI patients receiving vitamin K antagonists or direct oral anticoagulants. Revista Española de Cardiología (English Edition). https://doi.org/10.1016/j.rec.2024.03.013
Vancouver
Alperi A, Ptaszynski R, Pascual I, Del Valle R, Hernández-Vaquero D, Almendárez M, et al. Late bleeding events in TAVI patients receiving vitamin K antagonists or direct oral anticoagulants. Revista Española de Cardiología (English Edition). 2024. doi:10.1016/j.rec.2024.03.013
BibTeX
@article{Alperi2024,
author = {Alperi, Alberto and Ptaszynski, Raul and Pascual, Isaac and Del Valle, Raquel and Hernández-Vaquero, Daniel and Almendárez, Marcel and Antuna, Paula and Ludeña, Raul and Morís, César and Avanzas, Pablo},
title = {Late bleeding events in TAVI patients receiving vitamin K antagonists or direct oral anticoagulants},
journal = {Revista Española de Cardiología (English Edition)},
year = {2024},
doi = {10.1016/j.rec.2024.03.013}
}
EUVIMED